Investigational Drug Details
| Drug ID: | D201 |
| Drug Name: | Amprenavir |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00701 |
| DrugBank Description: | Amprenavir is a protease inhibitor used to treat HIV infection. |
| PubChem ID: | 65016 |
| CasNo: | 161814-49-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 |
| Structure: |
|
| InChiKey: | YMARZQAQMVYCKC-OEMFJLHTSA-N |
| Molecular Weight: | 505.627 |
| DrugBank Targets: | Human immunodeficiency virus type 1 protease |
| DrugBank MoA: | Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. |
| DrugBank Pharmacology: | Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. |
| DrugBank Indication: | For the treatment of HIV-1 infection in combination with other antiretroviral agents. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|